Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled PC945 in Healthy and Asthmatic Subjects
NCT02715570Phase 1Completed
- Sponsor
- Pulmocide
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of opelconazole in aspergillosis, sponsored by Pulmocide. Primary endpoints: Incidence of treatment emergent adverse events at 6 weeks, 12-lead ECG assessment at 6 weeks and 3 more. Started Oct 2017; status: completed.
02
Drugs
opelconazole
03
Conditions
aspergillosis
Beyond the preview
Go deeper on NCT02715570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715570.